Article Text

Download PDFPDF
Quadrupling or quintupling inhaled corticosteroid doses to prevent asthma exacerbations: the jury’s still out
  1. Amanda Jane Friend1,2
  1. 1 Department of Paediatrics, Leeds General Infirmary, Leeds, UK
  2. 2 School of Medicine, University of Leeds, Leeds, UK
  1. Correspondence to Dr Amanda Jane Friend, Department of Paediatrics, Leeds General Infirmary, Leeds, LS1 3EX, UK; amanda.friend{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Study 1

Study design

Double blind, randomised controlled trial.

Study question

Setting: UK.

Patients: 1871 adults and adolescents (mean age 57 years) who had a diagnosis of asthma, were being treated with inhaled corticosteroid (ICS) and had had at least one exacerbation requiring systemic glucocorticoid treatment in the preceding 12 months.

Intervention: Quadrupling dose of ICS at the early loss of asthma control (vs usual dose of ICS; both groups increased bronchodilator as required).

Outcomes: Rates of asthma exacerbation requiring treatment with systemic glucocorticoids or an unscheduled healthcare visit.

Main results

The study’s main results are summarised in table 1.

View this table:
Table 1

Summary of asthma exacerbations in patients treated with quadrupled dose of ICS vs usual-dose ICS during the 12-month trial period

View this table:


Temporary quadrupling of ICS dose at the early signs of loss of asthma control results in a lower rate of severe asthma …

View Full Text


  • Provenance and peer review Not commissioned; internally peer reviewed.